Vanilloid Receptor TRPV1 in Drug Discovery: Tar, Gomtsyan, Faltynek^+

Vanilloid Receptor TRPV1 in Drug DiscoveryTargeting Pain and Other Pathological Disorders\nAuthor(s): Arthur Gomtsyan, Connie R. Faltynek\nFormat: Hardback\nPublisher: John Wiley & Sons Inc, United States\nImprint: John Wiley & Sons Inc\nISBN-13: 9780470175576, 978-0470175576\nSynopsis\nExamines the emerging therapeutic role of TRPV1 TRPV1 is considered an integrator of noxious stimuli and therefore may be at a crossroads for pain transmission pathways. Because of its potential for managing multiple pain types, including osteoarthritis, chronic low back pain, neuropathic pain, and cancer pain, some consider it \""the holy grail\"" of pain management. This dedicated reference summarizes available data related to the potential therapeutic utility for TRPV1 ligands.\n\n With contributions from many of the world's leading experts on TRP channels, Vanilloid Receptor TRPV1 in Drug Discovery covers the important TRPV1 target for drugs to treat painful conditions such as inflammation,.